Servier, an independent international pharmaceutical group, and Day One Biopharmaceuticals, a commercial-stage biopharmaceutical company advancing treatments for pediatric cancers, announced a definitive acquisition agreement on March 6, 2026. Servier will acquire Day One for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion. The deal is expected to close in Q2 2026, according to a company press release.
Day One’s assets include Ojemda (tovorafenib), a type II RAF inhibitor that is FDA-approved for the treatment of relapsed or refractory pediatric low-grade glioma (pLGG) in patients aged 6 months and older. Tovorafenib is also currently being investigated in an ongoing Phase II clinical trial as a potential treatment for relapsed pLGG and advanced solid tumors harboring a known or expected to be activating RAF fusion. Additionally, the company is currently enrolling participants for a Phase III clinical trial evaluating tovorafenib’s efficacy as a treatment for pLGG requiring front-line systemic drug therapy.
Day One’s pipeline also includes Emi-Le (emilatug ledadotin), a novel ADC designed to target the B7-H4 protein, which is currently being studied in a Phase I clinical trial as a treatment for adenoid cystic carcinoma, as well as breast, endometrial, and ovarian cancers. Additionally, the company is currently enrolling patients in a Phase I clinical trial evaluating DAY3014, an ADC designed to target PTK7, as a treatment for locally advanced or metastatic solid tumors.
“This acquisition of Day One Biopharmaceuticals marks another decisive step in strengthening Servier’s position in rare oncology,” said Olivier Laureau, President, Servier, in the release. “It reflects our long-term commitment to investing in science that can make a meaningful difference for patients. This announcement is fully aligned with our 2030 ambition, and we believe that combining our expertise will accelerate innovation for people living with a rare cancer.
“Servier’s successful track record in rare cancers and its commitment to advancing targeted therapies makes it the ideal home for our portfolio as part of Day One’s mission to bring medicines to patients of all ages with life-threatening diseases,” said Jeremy Bender, Ph.D., CEO, Day One Biopharmaceuticals, in the release. “Joining Servier represents a unique opportunity to extend the reach of our science and our lead program in pediatric low‑grade glioma. Importantly, Servier’s dedication to the rare disease community preserves the patient‑first mindset that has defined our company since the beginning and has driven our deep commitment to the communities we serve.”
